GlassScriptPhysician profile
Thomas T Sands
NPI 1225272149
$10,080.48
in general payments reported to CMS, 2019-2025
24 companies · $1,186 in 2025
The $1,186 reported for 2025 was more than what 76% of Plastic Surgery providers received nationally (typical 2025 total: $380).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,373 · 2020: $485 · 2021: $494 · 2022: $1,098 · 2023: $2,963 · 2024: $1,481 · 2025: $1,186.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,656 · Travel and Lodging: $1,632 · Long Term Medical Supply Or Device Loan: $326 · Education: $16.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,656.31 |
| Travel and Lodging | $1,632.17 |
| Long Term Medical Supply Or Device Loan | $325.80 |
| Education | $16.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,692.48 | 2023-2025 | Natrelle Saline-Filled Breast Implants, Strattice Reconstructive Tissue Matrix Bps, Alloderm |
| Allergan, INC. | $3,571.66 | 2019-2022 | |
| Revance Therapeutics, INC. | $769.29 | 2024-2025 | Daxxify, Daxi |
| Merz North America, INC. | $440.43 | 2019-2023 | Xeomin |
| Integra Lifesciences Corporation | $379.82 | 2023-2025 | Durasorb Monofilament Mesh, Integra, Integra Dermal Regeneration Template |
| Sientra, INC. | $261.54 | 2019 | |
| Motiva USA, LLC | $222.83 | 2024-2025 | |
| Galderma Laboratories, L.P. | $215.48 | 2019-2024 | |
| Vertex Pharmaceuticals Incorporated | $66.94 | 2025 | |
| Baxter Healthcare | $62.00 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $61.06 | 2020-2024 | Exparel |
| Tela Bio, INC. | $45.90 | 2019-2023 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Davol INC. | $42.92 | 2022 | |
| Trevena, INC. | $41.98 | 2022 | |
| Heron Therapeutics, INC. | $31.87 | 2023 | Zynrelef |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apyx Medical Corporation | $30.08 | 2019 | |
| Innovation Technologies INC | $25.28 | 2025 | Irrisept |
| Convatec INC. | $25.06 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.42 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $18.22 | 2023 | Seglentis |
| Acella Pharmaceuticals, LLC | $16.28 | 2025 | NP Thyroid 60 |
| Lilly USA, LLC | $14.29 | 2024 | Mounjaro, Zepbound |
| Kerecis Limited | $13.90 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Sands listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.